CYP 2C19*2 Polymorphism and Clopidogrel Resistance
Author Information
Author(s): Alf-Aage Pettersen, Harald Arnesen, Trine B. Opstad, Ingebjorg Seljeflot
Primary Institution: Oslo University Hospital
Hypothesis
Does the CYP 2C19*2 polymorphism affect platelet function in patients treated with clopidogrel?
Conclusion
Patients with the CYP 2C19*2 polymorphism have significantly higher platelet reactivity when treated with clopidogrel compared to wild-type patients.
Supporting Evidence
- 29% of patients showed clopidogrel resistance as measured by VASP-PRI.
- 32% of patients showed clopidogrel resistance as measured by VerifyNow-PRU.
- Platelet reactivity was significantly higher in patients with the CYP 2C19*2 polymorphism.
Takeaway
Some people don't respond well to a heart medicine called clopidogrel because of a gene change. This study looked at how that gene change affects how well the medicine works.
Methodology
Patients with coronary artery disease were randomized to clopidogrel treatment, and platelet reactivity was measured using VASP-PRI and VerifyNow methods.
Potential Biases
Potential bias due to the single-center design and the specific population studied.
Limitations
The study was limited to a single center and may not be generalizable to all populations.
Participant Demographics
All participants were Caucasian with a mean age of 62 years, 79% male.
Statistical Information
P-Value
0.001
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website